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A B S T R A C T
The rapid development of engineered nanomaterials demands for a fast and reliable assessment of their health
hazard potential. A plethora of experimental approaches have been developed and are widely employed in
conventional toxicological approaches. However, the speciﬁc properties of nanomaterials such as smaller size
but larger surface area, and high catalytic reactivity and distinctive optical properties compared to their re-
spective bulk entities, often disable a straightforward use of established in vitro approaches. Herein, we provide
an overview of the current state-of the art nanomaterial hazard assessment strategies using in vitro approaches.
This perspective has been developed based on a thorough review of over 200 studies employing such methods to
assess the biological response upon exposure to a diverse array of nanomaterials. The majority of the studies
under review has been, but not limited to, engaged in the European 7th Framework Programme for Research and
Technological Development and published in the last ﬁve years. Based on the most widely used methods and/or
the most relevant biological endpoints, we have provided some general recommendations on the use of the
selected approaches which would the most closely mimic realistic exposure scenarios as well as enabling to yield
fast, reliable and reproducible data on the nanomaterial-cell response in vitro. In addition, the applicability of the
approaches to translate in vitro outcomes to leverage those of in vivo studies has been proposed. It is ﬁnally
suggested that an improved comprehension of the approaches with its limitations used for nanomaterials' hazard
assessment in vitro will improve the interpretation of the existing nanotoxicological data as well as underline the
basic principles in understanding interactions of engineered nanomaterials at a cellular level; this all is im-
perative for their safe-by-design strategies, and should also enable subsequent regulatory approvals.
1. Introduction
Nanotechnology enables the engineering of nanomaterials i.e. ma-
terials with any external dimension or internal/structural dimension in
the nanoscale, with remarkable new physical and chemical properties
that diﬀer from their bulk equivalents. This huge potential has led to an
increasing growth of research and development activities and created
an entire new class of materials which are used in a broad ﬁeld of ap-
plications such as in optics, electronics (e.g. for eﬃcient and cost-ef-
fective energy storage or their use as semiconductors) (Jariwala et al.,
2013), and in the medical ﬁeld as potential carriers for drug and gene
delivery or as diagnostic tools and contrast agents (De Jong and Borm,
2008). However, these new properties and the increasing industrial
production have raised concerns about potential adverse eﬀects for
human health; thus, a better understanding of cellular consequences
upon the direct exposure of (human) cells to these engineered nano-
materials (NMs) is prerequisite for their safe and successful use in any
applications.
The number of newly developed NMs with diﬀerent core materials,
sizes, shapes, and coatings is huge (McWilliams, 2016) and expectations
from society, consumer and regulatory bodies about their safety are
increasing. The characteristics of NMs can be inﬂuenced by various
physico-chemical parameters, in addition, a proper safety assessment of
every nanoform would be extremely cost-intensive and time-con-
suming. Moreover, the outcomes of animal testing regarding its pre-
dictive power for human beings exhibit certain limitations, mainly due
to physiological and biochemical species dissimilarities (Shanks et al.,
2009). In addition to that, the principle of the 3Rs – Replacement,
Reduction and Reﬁnement – has become an increasing public and legal
demand which ethically supports the replacement of animal use with
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more human-relevant alternatives that do not rely on in vivo testing
(Tornqvist et al., 2014). New concepts for eﬃcient, cheaper and evi-
dence-based testing strategies were proposed, based on the use of
human primary cells and cell lines (Council NR, 2007). In addition,
endpoints for health eﬀects and in vitro tests of regulatory interest for
conventional chemicals are contained in the Organisation for Economic
Co-operation and Development (OECD) and its test guidelines docu-
ments (TG) (OECD, 2013a). These in vitro tests are rather narrow in
their coverage of endpoints: they address genetic toxicity (e.g. (OECD,
2015a; OECD, 2014b; OECD, 2014c)), dermal absorption (OECD, 2004)
and skin and eye irritation (OECD, 2013b; OECD, 2015b; OECD,
2015c), endocrine disruption (e.g. (OECD, 2015d)), and few other se-
lected endpoints. But skin penetration has not been a major concern for
NMs while endocrine disruptor eﬀects for NMs are also not currently a
focus of research or regulatory concern. Rather, the most relevant in
vitro protocols for NMs align with the current major routes of NM ex-
posures. Besides dermal (NMs in cosmetic products) and oral (NMs in
food products) exposures the eﬀects due to NM inhalation are currently
considered to be the most relevant.
Cellular responses have been observed upon exposure to NMs and
currently several hypotheses regarding how NMs induce adverse cel-
lular eﬀects exist: (i) via oxidative means (the oxidative stress para-
digm) which then leads to pro-inﬂammatory eﬀects (Donaldson et al.,
2003), (ii) via the ﬁbre paradigm (Dorger et al., 2001; Donaldson and
Tran, 2004) (iii) through genotoxicity (Schins and Knaapen, 2007), and
(iv) via NM dissolution, i.e. release of potentially toxic ions and/or other
constituents (Bergin and Witzmann, 2013; Braakhuis et al., 2014). The
ﬁbre paradigm was highlighted in the paper by Poland et al. (Poland
et al., 2008) in which it was shown that multi-walled carbon nanotubes
caused granulomas in the peritoneal cavity. This paradigm however,
can only be attributed to nanoﬁbres in particular to those with the
speciﬁc characteristics of high rigidity and high aspect ratio NMs
(HARN) (Donaldson et al., 2010).
Other endpoints for NMs which can be examined in vitro include
those which test for the biological fate of NMs at the cellular or mul-
ticellular levels such as size exclusion criteria for given key cell types
(Zhu et al., 2013), and adverse eﬀects such as ﬁbrogenicity at these
levels of organization (Azad et al., 2013).
The goal of some ongoing research is to unravel modes of action
(MOA) of NMs using a plethora of functional assays which are designed
to indicate certain MOA relevant to the toxicity and/or fate of NMs and
to elucidate biokinetics of NMs, e.g. transport through interfaces like
air-liquid interface (ALI). It is anticipated that the obtained information
on MOA and biokinetics can later be used in weight of evidence ana-
lyses or tiered testing schemes in combination with other in vivo data,
leading to reduction and eventual replacement of in vivo tests.
These approaches may help to reduce and/or replace and reduce
animal testing according to the 3R strategy. With all these goals, it is
critical to use environmentally or occupationally relevant NM con-
centrations, and to be able to relate these in vitro test concentrations to
in vivo test exposures so that results can be correlated and used in a
regulatory context.
A comprehensive review about the relevance of in vitro nanotox-
icological studies in hazard assessment of NMs has been provided by
Park and colleagues in 2009 (Park et al., 2009) where comparison of
diﬀerent cell types and exposure duration was discussed, along with,
among others, dose response analysis and potential artefacts in the most
commonly used nanotoxicological assays. Since then many new studies
have been reported and this review has been developed based on an in-
depth summary of over 200 literature reports on the assessment of
biological hazard of NMs in vitro. The basis for the selection of the se-
lected and relevant results, protocols, and guidance documents, where
chosen from the project “A common European approach to the reg-
ulatory testing of Manufactured Nanomaterials” (NANoREG) (data de-
liverables from WP2, WP3, WP4 and WP5; www.nanoreg.eu; (Joint
Research Centre, JRC, 2016)), together with the OECD working party of
manufactured NMs (WPMN) activities. Peer reviewed publications from
other the 7th framework programme for research and technological
development (FP 7) projects and US research programmes have been
included. However, as some aspects were not comprehensively covered
in the above-mentioned literature pool, the authors have searched for
other relevant studies employing the publicly available search tools
(Web of Science, Pubmed, Google scholar). The aim of this overview is
to provide general recommendations for researchers employing in vitro
assays for assessment of NM hazard based on an extensive literature
study. All the recommendations proposed in this manuscript have been
developed based on the authors' perspective on the existing literature
data on this matter, as well on their experiences with in vitro studies for
regulatory submissions. Therefore, this overview of the most widely
used methodological approaches can serve as a basis for future research
directions including thoughts about reported pitfalls for some of the
methods and/or approaches.
2. General considerations for in vitro test methods
2.1. Nanomaterials
The description of the source of NMs and characterization data has
to be given with suﬃcient detail, including a thorough characterization
of both the pristine materials as well as in situ (before, during and after
the experiments). Additionally, the details of any dispersions methods
used for the experiments need to be reported (discussed in more details in
the subchapter 2.3 Dose metrics).The majority of the reviewed in vitro
studies report the primary sizes of NMs (transmission electron micro-
scopy (TEM), the hydrodynamic diameter (dynamic light scattering
(DLS)) and the zeta potential in water, and/or phosphate-buﬀered
saline (PBS) and/or cell culture medium (Stoehr et al., 2011; Anguissola
et al., 2014; Huo et al., 2015a; Shannahan et al., 2015), and speciﬁc
surface area (Huk et al., 2014; Armand et al., 2016a). In addition to
DLS, in some cases, nanoparticle tracking analysis (Di Cristo et al.,
2016), diﬀerential centrifugal sedimentation (Monopoli et al., 2011;
Wan et al., 2015) and photon cross correlation spectroscopy (Gliga
et al., 2014) are being used. Regarding light scattering techniques,
careful data interpretation is required as agglomeration and sedi-
mentation can occur simultaneously, particularly in the cell culture
medium. Particle agglomeration in the cell medium can be, depending
on the NM type, investigated by e.g. ultraviolet–visible spectroscopy
(UV–Vis) (Gliga et al., 2014). Speciﬁc surface area can be determined
by nitrogen adsorption (Huk et al., 2014); however this approach re-
quires relatively high material masses and is carried out on a powder
sample, which is not always feasible in nanotoxicological studies. De-
pending on the type, inductively coupled plasma (ICP) techniques in-
cluding ICP-optical emission spectroscopy (-OES) and ICP-mass spec-
trometry (MS) can be applied for mass concentration of the metal, and
UV–Vis for size determination of plasmonic NMs such as silver or gold
nanoparticles (NPs) (Stoehr et al., 2011; Gliga et al., 2014; Pang et al.,
2016). For soluble NMs, e.g. silver NPs or zinc oxide, kinetics of dis-
solution in cell culture media needs to be assessed over time (Huk et al.,
2014; Mu et al., 2014). Noteworthy, transformations of NMs in time
(particularly when stored in suspensions) has been suggested as one of
the most signiﬁcant contributors to the contradictory in vitro toxicity
results observed in the literature for identical NMs; hence, aging needs
to be addressed in parallel with the assessment of eﬀects (Izak-Nau
et al., 2015). Surface reactivity of NMs in a cell free environment can be
measured by the electron spin resonance (ESR) technique; brieﬂy,
presence of free radicals can be detected by using so called spin traps,
reagents that form adducts to stabilize the radicals, which then exhibit a
paramagnetic resonance detectable by spectroscopy (Monopoli et al.,
2011). Also, there are other techniques for detection of ROS/free ra-
dicals, for instance via cytochrome c reduction (Dikalov and Harrison,
2014), ferric-reducing ability of serum (FRAS) assay and dichloro-
ﬂuorescein assay (Pal et al., 2014).
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The importance of the individual properties also diﬀers with respect
to the exposure scenarios. For inhalation – which is accepted as one of
the most likely routes for NMs entering the body – the physico-chemical
properties of NMs aﬀecting material deposition and clearance from the
lungs are of particular importance. It is important to understand that
there is no individual particle property dictating this, but rather a
combination of them, predominantly: (i) size of individual particles or
agglomerates present in aerosols which inﬂuences the region of de-
position in the respiratory system, (ii) surface reactivity as a predictor
for induction of oxidative stress and pulmonary inﬂammation, and (iii)
shape which has gained attention especially regarding the ﬁbrous NMs
which are prone to cause asbestos-like eﬀects due to the diminished
clearance/increased biopersistence2 in the lungs (Utembe et al., 2015).
With submerged in vitro studies, biodurability of NMs e.g. dissolution
rate is also important, particularly for fast dissolving particles (as the
eﬀect is driven by their chemical composition), e.g. the released ions
may present an important source of NM toxicity. When such dissolving
NMs are phagocytized by alveolar macrophages the dissolution rate
might even be accelerated compared to that in the epithelial lining ﬂuid
which can lead to enhanced inﬂammation in the lungs (reviewed in:
(OECD, 2015c)).
Until now, no optimal set of techniques has been proposed for
characterizing the physicochemical properties either for a speciﬁc type
of NMs or for a general assessment of a variety NMs. However, else-
where in this journal, Lowry et al. (2017 - in this issue) propose a
minimal set of such properties broadly applicable to NM regulatory
assessments (Lowry et al., 2017 - in this issue). In addition, the practical
aspect of the techniques available at the researcher's organization needs
to be taken into account. However, it is recommended that not only one
single technique, but a combination of the appropriate ones should be
employed for an accurate description of NMs. Such a strategy has also
been proposed in a review from the FP 7 NanoTEST project (Dusinska
et al., 2015) and has already been indicated previously by the European
food and safety authority (EFSA (EFSA, 2011)), the Scientiﬁc Com-
mittee on Consumer Safety (SCCS (SCCS, 2012)) and the Scientiﬁc
Committee on Emerging and Newly Identiﬁed Health Risks (SCENIHR
(SCENIHR, 2015)) guidance on use of NMs in food/feed, cosmetics and
medical devices. The properties considered to be the most relevant for
the toxicology of NMs include size, size distribution, shape, agglom-
eration state, density, surface area, surface charge, surface reactivity,
solubility and crystalline phase (Gordon et al., 2014). In addition, the
eﬀective density which is an indicator of possible agglomerate forma-
tion (DeLoid et al., 2014); hydrophobicity (Farcal et al., 2015) and the
extent of impurities/contaminants (Pulskamp et al., 2007) are im-
portant factors which can determine the hazard of the NMs.
2.2. Cell cultures
In order to repeat previously published experiments, and for inter-
laboratory comparisons, it is important to report the cell source, pas-
sage number, and precise cell culture method (Gstraunthaler and
Hartung, 2002). This also includes e.g. the brand of the laboratory
plastics used for culturing and in the assays, as well as a thorough de-
scription of the cell growth, morphology and diﬀerentiation before and
during the test performance. Such a detailed description and char-
acterization of the cells used is unfortunately missing in most of the
reviewed publications, which makes replication or comparison very
diﬃcult. In some of the publications the cell proliferation rate, i.e. cell
growth, was assessed (Armand et al., 2016a; Izak-Nau et al., 2015; Huk
et al., 2015a) and the morphology has been observed by bright ﬁeld
microscopy (Huk et al., 2014).
The use of cell culture medium (foetal calf or bovine serum (FCS/
FBS)), and the choice of the cultivating material (cell culture ﬂasks in
which the cells are grown) are not standardized. Also, the time of the
cells in culture, meaning the passage number of cells in the experiment
and the exposure duration, signiﬁcantly diﬀers among the publications.
It is important to justify the selection of the cells used. Fibroblasts
(usually cell lines) (Fig. 1b) are commonly used to assess pro-ﬁbrotic
signals (Azad et al., 2013; Wang et al., 2015), whereas the rationale
behind the selection of macrophages (Fig. 1a) is based on the fact that
they are primary cells and that they act as the ﬁrst responders upon
exposure to NMs (Herd et al., 2015; Palomaki et al., 2015). In addition,
many studies use intestine or lung epithelial (Fig. 1c) cells because they
represent the primary organs of entry for NMs (Rothen-Rutishauser
et al., 2012).
In most of the studies screened, cell lines are preferred over primary
cells due to their homogeneity and greater stability; this yields better
data reproducibility as it is impossible to exactly reproduce the isolates
batches of primary cells. Primary cultures also face limitations such as
the lack of tissue availability, limited number of cells that can be
yielded from each isolation and donor-speciﬁc variations. Yet the ad-
vantage of primary cells is that they can (depending on the cell type)
survive for prolonged periods of time thus enabling it more possible to
analyse subacute or sub-chronic exposure duration eﬀects in vitro with
respect to the exposure duration. However, there are also other lim-
itations of in vitro sub- and chronic exposure studies, such as the fast cell
division of most of the cell lines and possible de-diﬀerentiation during
prolonged time in culture. Also certain cell lines can be used for long-
term experiments (Thurnherr et al., 2011), however they have to be
subcultured routinely because of their continuous growth, and thus
diﬀerentiation might not be well reﬂected. With initial testing of a new
NM, the use of primary cells might be preferred over cell lines since in
Fig. 1. Phase contrast light microscopy images of human cell lines: macrophages (THP-1, 1a), ﬁbroblasts (MRC-5, 1b) and alveolar epithelial cells (A549, 1c).
2 For deﬁnition of biopersistence and biodurability see Utembe et al., 2015: Bio-
persistence of is deﬁned as the extent to which they are able to resist chemical, physical,
and other physiological clearance mechanisms in the body. Biodurability, deﬁned as the
ability to resist chemical/biochemical alteration, is a signiﬁcant contributor to bio-
persistence.
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certain cases cell lines might not be responsive for certain cell reactions
because of their de-diﬀerentiation in culture. In addition, the use of
human cell lines is supported since they more closely mimic human
responses in comparison to rodent cell lines; rodent cell lines might,
however, be important to include for comparison of the results with
animal data.
Recently, the importance of speciﬁc disease-related endpoints and
receptive relevant experimental conditions has been highlighted. One
example is the human pulmonary edema model on a chip which is a co-
culture of human alveolar epithelial and pulmonary microvascular
endothelial cells stimulated with interleukin-2 (Huh et al., 2012). It is
also emphasized that more advanced human in vitro models should be
used to assess interactions and possible eﬀects (Wick et al., 2014).
However, so far no standardized and validated three-dimensional (3D)
model, neither healthy nor diseased, has yet been accepted or approved
for any NM type and application.
It is well-known that traditional in vitro cell monocultures can lack
phenotypic details, physiological functions or only partially depict the
complex cross-talks between cells. 3D culture models have been de-
scribed to have the potential to be more predictive in toxicology testing
thus ﬁlling a gap between two-dimensional (2D) system and animal
experiments (Alepee et al., 2014). There are multitudes of new co-
culture or 3D cell culture systems for diﬀerent tissues developed during
the last years, combining several relevant cell types for the same organ
into one model-system which can be used to assess the interaction with
NMs (Wick et al., 2014). However, only a few were carefully validated
to whole organ or in vivo responses (Astashkina and Grainger, 2014).
For instance, co-cultures of skin tissue composed of human epidermal
keratinocytes and dermal ﬁbroblasts which have been described in the
90s (Osborne and Perkins, 1991). As an alternative in vitro method for
hazard identiﬁcation of irritant substances reconstructed 3D human
epidermis-based human models (OECD TG 439) (OECD, 2015c) have
been designed which closely mimic the biochemical and physiological
properties of the human epidermis. This assay has already been applied
to test the irritation potential of NMs (Kim et al., 2016). In addition,
since 2013 the OECD TG 431 (OECD, 2014a) is approved to use this in
vitro system allowing the identiﬁcation of corrosive chemical sub-
stances and mixtures; more eﬀorts are required to develop and validate
such advanced in vitro models for other tissue types. As of 2009, the
OECD TG 437 Bovine Corneal Opacity and Permeability (BCOP) (OECD,
2013b) test method has been introduced to determine severely irri-
tating substances. In the recent study by Kolle and colleagues (Kolle
et al., 2016) a broad panel of NMs was tested using the combination of
the EpiOcular™ Eye Irritation Test (OECD TG 492 (OECD, 2015b)) and
the BCOP (OECD TG 437 (OECD, 2013b)). It has been proposed that
this two-tier non-animal testing strategy could replace more traditional
animal tests for these endpoints.
The use of cell lines in monoculture systems is recommended for the
ﬁrst stage NM hazard evaluation as they allow a better reproducibility
and comparability for interlaboratory comparison of either the same
NM type or among diﬀerent NMs. Selection of cell lines strongly de-
pends on the research question and the investigated endpoints. For a
higher tier evaluation, the use of primary human cells and/or co-culture
models is preferred to better understand NM mechanistic behaviour in
more complex systems; however, such systems might be diﬃcult to
apply in high-throughput assays due to costs and reproducibility.
2.3. Dose metrics
2.3.1. Dispersion of NMs and physico-chemical NM characterization in
suspensions
Harmonized protocols for NM suspension preparation are particu-
larly important for the in vitro tests as both dispersion protocol and the
cell culture media signiﬁcantly alter their characteristics. For example,
the standard operating procedure (SOP) developed under the
Nanogenotox project aims to produce a highly dispersed state of NMs
by ethanol pre-wetting of hydrophobic powders, followed by dispersion
bovine serum albumin in water (NanoGenotox Joint Action report,
addressed in (Farcal et al., 2015)). Besides powders, NMs can be ob-
tained in pure or buﬀered water suspensions. Regardless, sonication
might be required prior to addition to cell culture medium, but, im-
portantly, this must be performed in water and subsequently diluted in
culture media to the desired concentration for application to cells
(DeLoid et al., 2017). Since probe sonication can induce production of
reactive oxidative species (ROS) in suspension (and protein denatura-
tion), ROS content must be checked using the cell free assays based on
ﬂorigenic dyes which measure activity of ROS activity (Zhao and
Riediker, 2014). In order to avoid interference of serum proteins with
NMs, in vitro cell culture experiments can also be performed in serum-
free medium, i.e. without the addition of FBS/FCS, or with reduced
FBS/FCS content. Importantly, the amount of serum proteins, their pre-
treatment (e.g. heat-inactivation) and the source can strongly eﬀect
NMs interactions with cells (Lesniak et al., 2010; Lesniak et al., 2012).
It is important to mention that the cell behaviour in serum-free con-
ditions has to be thoroughly observed. The use of stabilizers with mu-
tagenic or toxic potency in the synthesis and dispersion preparations of
NMs should be avoided where possible. For example, the detergent
Tween 80 (already at a concentration of 0.008% w/v) caused a strong
mutagenic eﬀect whereas anionic surfactants (e.g. sodium dodecyl
sulphate (SDS; 0.05%) and a polysaccharide chitosan (0.05% in 0.1%
acetic acid) were found to be only weakly mutagenic (Huk et al.,
2015a). Pluronic F127 has been described to eﬀectively disperse carbon
nanotubes (Kastrisianaki-Guyton et al., 2015); however, it also has been
reported that the surfactant alone (e.g. Pluronic dispersants) can induce
adverse eﬀects, particularly upon sonication (Wang et al., 2013). It is
diﬃcult to recommend an optimal dispersant for all NMs since they
diﬀer in physico-chemical properties and it is, therefore, mandatory to
include appropriate controls with the dispersant alone. Also, NM sus-
pensions need to be tested for endotoxin presence such as lipopoly-
saccharide (LPS) using commercially available assays, for instance the
limulus amebocyte lysate (LAL) endochrome test. At the moment, three
diﬀerent approaches of the in vitro LAL assay formats are available: gel-
clot (semi-quantitative), turbidimetric, and chromogenic (quantitative)
(Farcal et al., 2015; Dobrovolskaia et al., 2009; Giannakou et al.,
2016a). As NMs interferences with the LAL assays are expected (due to
the instance high adsorption capacity, optical properties, hydro-
phobicity, surface charge, and catalytic activities), the selection of the
appropriate format is speciﬁc to the NM types and at least two assay
formats should be used as to avoid either over- or underestimation of
the endotoxin levels (Dobrovolskaia et al., 2009; Giannakou et al.,
2016a). In all the assays, it is important to include: (i) “NM-only”
controls in order to screen for the potential positive responses caused by
NM interferences with the optical reading (absorbance, luminescence or
ﬂuorescence), (ii) “NM-plus-assay-reagents” controls to eliminate pos-
sible false positive responses arising from NM catalytic properties, i.e.
the assay is run in the presence of NMs and all the assay reagents but in
the absence of the tested biological sample, and (iii) the “inhibition/
enhancement controls” for identifying false-positive or false-negative
signals resulting from the interaction of NMs with the inﬂammatory
signalling mediators, such as endotoxins and/or cytokines
(Dobrovolskaia et al., 2009). Several approaches have been used tra-
ditionally to resolve interference of test samples with the LAL assays,
e.g. diluting the test sample. However, if the interference cannot be
overcome, additional methods may be required, such as: (i) extraction
of endotoxin from NM formulation, e.g. by depyrogenation (dry heating
in high temperature; yet this might have severe consequences on NM
properties) or ﬁltration (cannot be used for all the NM types), auto-
claving and irradiation, as well as formaldehyde, ethylene oxide and
gas plasma treatments. Furthermore, (ii) the endotoxin presence ana-
lysis per se can be done on particle free supernatants obtained by either
dialysis of centrifugation. Overall, the optimal way is to avoid NM
contamination by NM preparation using sterile, endotoxin-free
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environment and reagents (Dobrovolskaia et al., 2009; Giannakou
et al., 2016a).
Most of the in vitro experiments require a dilution of the NM stock
solution in complex media, i.e. serum supplemented cell culture
medium. A standard complete cell culture medium can be described as
a buﬀered solution containing proteins such as serum albumin, globu-
lins, other biomolecules such as vitamins and amino acids, and ionic
salts (e.g. minimum essential medium (MEM), Dulbecco's modiﬁed
Eagle medium (DMEM) or Roswell Park Memorial Institute
(RPMI1640), and supplemented with 10% FBS or human-derived
serum, as well as antibiotics (usually penicillin-streptomycin). Thus, the
behaviour of NMs in such a complex environment will be dictated by
the interaction with these components and can lead to dissolution,
agglomeration, protein adsorption, i.e. the formation of a protein
corona, or detachment of ligands (reviewed in: (Urban et al., 2016;
Moore et al., 2015). It is therefore absolutely mandatory to characterize
the NMs in the respective cell culture media because this will strongly
aﬀect the NM-cell interactions. It is recommended that primary NM
size, hydrodynamic size and zeta potential values in water (or the re-
levant dispersant) are evaluated; for experiments under submerged
conditions, the latter two need to be assessed also in cell culture
medium. The state of agglomeration needs to be considered in all the
media used (or compared water vs. cell culture medium). However, the
characterization requirements strongly depend on the experimental
setup therefore this might require experiment speciﬁc adjustments.
Besides the exposure conditions, e.g. particle concentrations, height
of the medium on top of the cell layer, and perfusion with medium, cell
culture medium composition is the most important factor inﬂuencing
NM uptake and cellular responses (Meindl et al., 2017). The most im-
portant medium components which inﬂuence NM behaviour in cell
culture media are the proteins (type and content, usually deriving from
the serum source) which are aﬀecting their state of agglomeration and
sedimentation as well as their overall biological identity. The latter is
well-known as the “protein corona paradigm” (Monopoli et al., 2011;
Wan et al., 2015; Lundqvist et al., 2008; Monopoli et al., 2012;
Cedervall et al., 2007; Walczyk et al., 2010). It has been noted that the
type of NM protein corona, generated as a consequence of a speciﬁc test
medium, can strongly inﬂuence the uptake and toxicity of individual
NMs such that the in vitro results may be test system-speciﬁc (Gliga
et al., 2014; Kim et al., 2014; Docter et al., 2015). It should be noted
that adsorption of proteins on NM surface may function as steric pro-
tection colloids causing deagglomeration of NMs in protein-rich media
(Schulze et al., 2008). Nonetheless, the use of proteins in cell culture
media needs to be adapted with respect to the research question, i.e.
with the estimated exposure route. For example, in experiments using
lung cells in vitro, the use of pulmonary surfactant is recommended
since inhaled NMs will come in contact with the surfactant covering the
aqueous lining layer leading to surfactant covering of the materials
(Schleh et al., 2013). In contrast, when investigating other exposure
routes, in particular when mimicking NMs in the systemic circulation,
the addition of blood serum proteins is prerequisite for a reliable cell
exposure to NMs.
Protein adsorption on the NM surface can be, for instance, analysed
with SDS-polyacrylamide gel electrophoresis gel based approaches
which can be additionally coupled with e.g. electrospray liquid chro-
matography mass spectrometry (LC-MS/MS) (Wan et al., 2015), or the
ability or a potential of NMs to adsorb proteins can be simply evaluated
using the bicinchoninic acid assay (Pang et al., 2016). Depending on the
NM type, hyperspectral imaging can be used to follow the extra- and
intracellular alterations such as biomolecule adsorption and alteration
in surface chemistry (Shannahan et al., 2015).
2.3.2. Realistic NM concentrations and dose delivered onto the cell surface,
i.e. dosimetry
In order that the outcomes of in vitro studies can be useful in a
regulatory context the results must be transformed to concentrations
that would be meaningful in an in vivo setting. Concentrations of NMs
and their respective doses should be realistic, i.e. relevant to human
exposure scenarios such as occupational exposure limits for NMs
(Gordon et al., 2014), e.g. using a model for calculation of the deposited
NM concentrations based on the concentration in suspension
(Hinderliter et al., 2010). For the in vivo dosimetry the evaluation can
be done, for instance, applying the In vitro sedimentation, diﬀusion and
dosimetry model (ISDD) model (Hinderliter et al., 2010) or the mul-
tiple-path particle dosimetry (MPPD) model (described below) (Cassee
et al., 2002). Only in few studies, hydrodynamic size is compared in a
time course before and after the exposure in cell culture media (Di
Cristo et al., 2016; Gliga et al., 2014).
It should be noted that in mechanistic studies, unrealistically high
NM concentrations (used both in in vivo rodent and – even to a higher
extent – in in vitro assays) are sometimes required for determination of
both the eﬀect and no-eﬀect levels of NMs. However, for assessment of
potential NMs hazard to humans, NM concentrations should be selected
based on realistic human exposure measurements, i.e. ﬁeld studies.
Nevertheless, such data are often scarce or unavailable for the majority
of NM types. Therefore, the dose estimations are often calculated based
on worst case assumptions (Dekkers et al., 2016). Overall, for trust-
worthy nanotoxicological in vitro data, ﬁrst of all, there is a need for
measurement data or at least estimations of realistic human exposure to
NMs via the dermal, oral or respiratory route. In addition, it is re-
commended that the concentrations used in the submerged settings do
not greatly exceed the level at which agglomeration is enhanced in
order to avoid side eﬀects of agglomeration and sedimentation aﬀecting
data interpretation (Huk et al., 2015b; Hirsch et al., 2011). For sus-
pension experiments, use of 1–100 μg NMs/mL has been recommended,
conditionally with the lower and higher limits at 0.125 and 200 μg/mL,
respectively (Farcal et al., 2015). This has to be considered regardless of
the fact that the maximum eﬀect (100% cell death) cannot always be
achieved as the administration of too high doses of NMs could cause
interferences with the assays (Krug and Wick, 2011; Stone et al., 2009).
The eﬀect of NMs can be categorized depending on the calculated half
maximal inhibitory concentration (IC50) and the concentration that
gives half-maximal response (EC50) values (Farcal et al., 2015). A re-
view article by Landsiedel and colleagues (Landsiedel et al., 2014)
noted that high concentrations in vitro do not correlate with in vivo test
concentrations. Most studies test acute exposure with high NM con-
centrations, and there are only a few describing long-term exposures
over weeks or months to sub-chronic exposures (Armand et al., 2016a;
Chen et al., 2015; Armand et al., 2016b). Some in vitromethods, such as
ALI systems and other systems which examine how NMs cross other
barriers, can largely avoid reverse dosimetry models as they oﬀer de-
termination of deposited NMs dose, and at the same time more closely
have recently emerged as an optimal solution to overcome the issue
with suspension cultures by a direct deposition of the NM onto the lung
cell surface (Huh et al., 2012; Chortarea et al., 2015). The advantage of
such systems is that the material mass can be fully controlled with
monitoring the material deposition on the lung cell surface on-line,
allowing the determination of a dose-eﬀect correlation.
It is diﬃcult to provide the justiﬁcation for a deﬁned concentration
of NMs in in vitro assays; however, there are some approaches to un-
derstand the relation between real-world exposure scenarios and in vitro
test concentrations. Since inhalation is assumed to be the major route
for NMs entering the human body, the majority of dosing methods are
found for the respiratory tract (Oberdörster et al., 2007; Oberdorster
et al., 2015). One approach describes the measurement of NM con-
centration in the air in manufacturing laboratories to identify input
levels for estimating NM mass retained in the human lung using the
MPPD model. Based on a review of published NM concentration in the
air at the manufacturing sites and using the MPPD model, Gangwal and
colleagues (Gangwal et al., 2011) provided an estimation of the al-
veolar mass for selected NMs (i.e. titanium dioxide NPs, silver NPs and
carbon nanotubes). The calculations propose that the estimated
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alveolar retention of the NMs is likely to be proportional to a working-
lifetime (45 years) exposure duration which can be expected in the
range of 10 to 50 μg/cm2 (alveolar mass retention). Based on the model,
this corresponds to rather high concentrations of NM solutions used in
in vitro studies (30 to 400 μg/mL) typically reported in the literature
(Gangwal et al., 2011). Nevertheless, it is important to note that me-
chanisms of biological response to a high single dose compared to a
repeated low dose exposure are expected to diﬀer substantially.
Therefore, in general, the in vitro assays cannot be directly correlated to
life-time exposure scenarios, but rather to a daily exposure. A closer
approximation to a subchronic exposure scenario can be achieved by
repeated exposures to a substance (e.g. NMs) in vitro, even over a several
week period. However, there the limitations with in vitro model systems
since they might not be sustainable for subchronic durations. Therefore,
experiments with such high concentrations and shorter durations have
to be carefully interpreted since one has to consider that the cells re-
ceive a high concentration within a brief 24 h period and it might not
be appropriate refer to as a life-time exposure when cell cultures are
used. Besides the dose itself, the post-exposure time may signiﬁcantly
aﬀect the NM dose rate. Even with similar lung burden observed after a
short vs. long-term exposure, the dose rates might be signiﬁcantly dif-
ferent in the in vivo situation due to the contribution of NM clearance.
Lower dose-rates have been observed to lead to a longer-lasting and
more persistent inﬂammation (Keller et al., 2014). Only a few pub-
lications have been found that consider such calculations. Occupa-
tionally relevant in vivo exposures (10 to 80 μg/mouse) and pulmonary
ﬁbroblast in vitro exposure studies, using in vivo dose equivalents (0.02
to 0.2 μg/cm2), resulted in a dose-dependent transient pulmonary in-
ﬂammation followed by ﬁbroblast cell proliferation, alveolar wall
thickening, and collagen I production culminating in persistent pul-
monary ﬁbrosis (Shvedova et al., 2008; Wang et al., 2010).
In addition to the aforementioned extracellular biological transfor-
mation of NMs in cell culture medium, also intracellular NM alterations
such as biomolecule adsorption, alterations in surface chemistry and
dissolution inside cellular compartments may inﬂuence cellular re-
sponses to NMs. For instance, using the hyperspectral dark ﬁeld mi-
croscopy, such alterations of NMs in diﬀerent intracellular compart-
ments can be observed (Shannahan et al., 2015). The spectra of
internalized NMs can be compared to that of NMs alone, or in condi-
tions mimicking cellular compartments, e.g. artiﬁcial lysosomal ﬂuid, or
in other relevant biological environment such as lung or intestinal
ﬂuids.
When interpreting nanotoxicological data, attention should be paid
to the administered and applied doses as well as with the information
about human realistic exposure data. Discrepancy between the ad-
ministered and deposited doses might be substantial. The deposited
dose can be evaluated with dosimetry models or by experimentally
assessing NM concentration on the cells or intracellularly, for instance
with ICP-based techniques. However, as the human exposure con-
centrations and ﬁnal doses are not available for many NM types, the
comparison might be diﬃcult. Nevertheless, the existing nanotox-
icological data can provide a ﬁrst idea on NM hazard and can serve as a
basis for comparison of the potential hazard diﬀerent NM types.
Both issues have been extensively discussed in the past and im-
provements are possible. The interpretation of NM-related cellular ef-
fects requires thorough understanding about the dose and number of
NMs deposited on the cell surface. It has been reported that when
comparing NMs with diﬀerent properties – such as with the same
chemical composition but diﬀerent size, shapes or surfaces – reverse
trends for cytotoxicity have been reported for the results presented as
mass vs. surface area NM or number (Huk et al., 2014; Huk et al.,
2015a). Dose metrics can be expressed in mass (μg/mL), surface area
(m2/mL) or particle number (n/mL); in the majority of studies the
concentrations are expressed in mass units, i.e. as NM dispersion con-
centration (μg/ml), as NM mass per surface of exposure cells (μg/cm2)
or NM mass per individual cell (μg/cell), although it has been claimed
that the number or volume of particles determines cytotoxicity of NMs
(also reviewed in: (Park et al., 2009)). However, in inhalation tox-
icology as well as generally for in vitro toxicity, a correlation with
surface area has been proposed as a recommended dose expression
(Park et al., 2009; Oberdorster et al., 2005; Braakhuis et al., 2016) as it
can be compared to in vivo exposure results (yet attention to diﬀerences
in the method of exposures should be considered) (Elliott et al., 2017).
The use of mass or number concentration per cell seems to be parti-
cularly appropriate for NM testing; however, it is recommended to
express concentrations in all the three dose metrics (mass, surface area
and number). This allows conversion from one dose to another when
needed for determination of the best ﬁtting dose metric for a toxic ef-
fect. If the particles are thoroughly characterised, this should be
anyhow feasible.
Depending on the size (and agglomerate density), NMs might sedi-
ment slower compared to bulk materials, and can be delivered to the
cell surface via diﬀusion (Limbach et al., 2005). Thus, deposition of
NMs concentration/dose onto the per cell surface is the dominant factor
determining the rate of uptake and not particle number NM con-
centration per volume or total surface area of the material (Limbach
et al., 2005; Teeguarden et al., 2007). Hinderliter and colleagues have
developed the ISDD to estimate the deposited NMs dose by a compu-
tational approach (Hinderliter et al., 2010) if experimental methods are
not available. Applying a simulation approach, the ISDD model calcu-
lates the delivered dose and rate of transport of NMs using readily
available parameters such temperature, media height, particle size in
solution, agglomeration state and particle density. The model has been
developed for spherical particles, though for ﬁbres such a modelling
approach does not yet exist. For instance, the ISDD model has been used
to calculate the deposited concentration of silver NPs on lung cells. The
results showed that a rather high concentration of 30 μg/mL applied for
24 h under submerged conditions reﬂect a working lifetime rather than
an acute exposure scenario and result in both increased cytotoxicity and
inﬂammatory responses (Herzog et al., 2014). However, it is of course
questionable as to whether the eﬀects observed within 24 h really re-
ﬂect a long-term response and such results have to be interpreted
carefully. Some other studies have recently been published on the im-
provement of the prediction of in vitro dosimetry, for instance by
measuring the eﬀective density of nano-agglomerates in suspension
(DeLoid et al., 2014) or to improve the detection of particle size and
agglomeration in complex biological media by using depolarized DLS
(Balog et al., 2015). Although all these eﬀorts to describe and measure
the deposited NM concentration have increased and proved to be re-
levant within hazard and/or risk assessment, not many publications
have employed such approaches thus far.
3. Interaction of NMs at the cellular level and their modes of
actions
3.1. Biopersistence of NMs in relevant environments
The behaviour of NMs in physiological ﬂuids, such as in mucus
resembling the environment in the gastro-intestinal and respiratory
tracts, in aqueous lining layer covered by surfactant (lung par-
enchyma), in blood or lymphatic ﬂuid, is important to study because
this might change their physico-chemical properties, such as size, ag-
glomeration state and zeta potential, i.e. stability (Urban et al., 2016).
The evaluation of NMs' biodegradability and biodurability is also re-
commended in mimicked intracellular lysosomal compartments, e.g.
using either artiﬁcial lysosomal ﬂuid or cell lysates (Shannahan et al.,
2015; Gliga et al., 2014).
Regarding the inhalation route of exposure in vivo, lung lining ﬂuid
which is covered with pulmonary surfactant is the ﬁrst biological
structure with which inhaled and deposited NMs interact in the alveolar
compartment. Pulmonary surfactants consist of lipids (90% w/w;
mainly phospholipids) and proteins (10% w/w; mostly speciﬁc
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surfactant proteins but also common proteins such as albumin or im-
munoglobulins are present (Wohlleben et al., 2016). Thus the interac-
tion between NMs and surfactants is required for a complete NM
characterization in relevant biological ﬂuids. It has been proposed that,
besides NM aerodynamic size, lipid aﬃnity of NMs may strongly in-
ﬂuence their deposition in vivo, meaning lipophilic NMs with high af-
ﬁnity towards pulmonary surfactants exhibit higher lung burden com-
pared to hydrophilic NMs (Wohlleben et al., 2016). This is an important
consideration also for the NM impact at the alveolar ALI (Marchetti
et al., 2015).
It is diﬃcult to compare the existing experimental data as diﬀerent
surfactant models have been used, including both the semi-synthetic or
natural surfactant preparations. For example, evaluation of the surfac-
tant protein D adsorbed to NMs with SDS-page and immunoblotting is a
recommended approach (Marchetti et al., 2015) as it is applicable to a
variety of NMs regardless of their composition, shape and size.
Among the studies under review, we have not found one applying
the mineral ﬁbre biopersistence protocol (Bernstein et al., 1994) to NMs
directly. However, since length, thickness and biopersistence of ﬁbre
shaped MNs (i.e. carbon nanotubes), is an important factor for the
prediction of the pathogenicity of ﬁbres (Donaldson et al., 2013), bio-
durability of the NMs in relevant biological ﬂuids needs to be addressed
not only in NM inhalation studies, but in any outcomes related to their
intracellular fate and distribution also in other cell types. In particular
regarding the pulmonary exposure studies, as the agglomeration state
and thus biopersistence of not only ﬁbrous NMs but also other types of
NMs is especially important for uptake and particle processing in al-
veolar macrophages (Goode et al., 2015).
3.2. Key physico-chemical parameters of NMs determining cellular uptake
and fate
As recommended by the OECD the physico-chemical properties of
NMs, including primary particle size, size distribution, composition,
surface charge, shape, speciﬁc surface area, zeta potential, crystallinity,
crystalline size, dissolution and solubility and redox potential should be
considered in hazard assessment studies (OECD, 2009) since these
parameters strongly inﬂuence the behaviour in physiological ﬂuids and
thus the uptake. In addition, agglomeration and aggregation, bio-
persistence, protein bio-corona, and dosimetry of the tested NMs are
also recommended for consideration. Since most of the publications do
not provide a detailed characterization of the NMs in complex cell
culture media, the correlation of NM properties with cell uptake and
intracellular fate is diﬃcult. In addition to NM size and hydrophobicity,
surface charge has been proposed to be one of the most factors inﬂu-
encing uptake of NMs in cells and their cellular fate (Fröhlich, 2012).
3.3. Uptake mechanisms
The most important biological parameters determining NM cellular
uptake in vitro are cell size, proliferation rate and growth characteristics
and expression of surface receptors involved in speciﬁc uptake-routes
(Meindl et al., 2017). The uptake of NMs occurs via endocytotic path-
ways, i.e. phagocytosis which involves the ingestion of large particles or
NM agglomerates (> 0.25 μm in diameter) and pinocytosis including
macropinocytosis, clathrin-, and caveolin-mediated endocytosis and
clathrin- and caveolin-independent endocytosis involving the ingestion
of smaller particles (< 0.15 μm in diameter) (Conner and Schmid,
2003). NMs have been shown to be internalized in the cells mainly by
pinocytosis, however the speciﬁc mechanisms diﬀer with respect to the
NM characteristics and cell types (Mahmoudi et al., 2012; Unfried et al.,
2007). Other pathways have been reported since NMs of diﬀerent
composition have been found not to be membrane-bound, thus in-
dicating alternative entering pathways (Geiser et al., 2005; Mu et al.,
2012; Lesniak et al., 2005; Rothen-Rutishauser et al., 2006). For ex-
ample, passive diﬀusion through membrane pores and passive uptake
by van der Waals or steric interactions (subsumed as adhesive inter-
actions) have been described (Rimai et al., 2000). Noteworthy, the
composition of cell culture medium strongly aﬀects uptake mechanism,
most importantly by the protein content, and by exposure conditions,
such as the NM concentration and factors related to the height of the
cell culture medium covering exposed cells as well as, if applicable,
medium perfusion (Meindl et al., 2017). Regarding NM characteristics,
NMs surface charge is currently considered as one of the most im-
portant parameters. It has been suggested that cationic NM penetrate
more easily through mammalian cell membranes in comparison to
positive charged ones (Harush-Frenkel et al., 2008). Importantly, the
well-studied and accepted protein corona paradigm (Lundqvist et al.,
2008; Cedervall et al., 2007) in the nanotoxicology also has to be
considered (Wan et al., 2015; Monopoli et al., 2012; Walczyk et al.,
2010), since the protein corona formed on NM surface may signiﬁcantly
alter the NMs surface charge as seen by the cells. This means that even
on NMs with diﬀerent primary surface charges (even of opposite
charges), a protein corona with a similar or the same charge may be
formed in cell culture medium where exposure to cells occurs [82, 119
and reviewed in: {Corbo et al., 2016 #4276]. The latter needs to be
taken into account when interpreting the surface charge of NMs with
cellular uptake.
Noteworthy, the uptake mechanisms for the same NMs into diﬀerent
cell types can also vary (Tedja et al., 2012). All of the previously pre-
sented endocytotic pathways do have at least one aspect in common,
that the internalized particle is ultimately located in an intracellular
vesicle. Endocytosis of NMs results in the localisation of the particles
ﬁrst in early endosomes, then late endosomes, and those ﬁnally fuse
with lysosomes (Li et al., 2013). For instance, the clathrin-mediated
pathway has been reported to be involved in the uptake of chitosan NPs
in A549 cells (within 1 h to 4 h) (Huang et al., 2002).
3.4. Intracellular localization of NMs
The intracellular distribution pattern of NMs is an important factor
in investigating their biological responses; however diﬀerent NM types
require distinctive analytical methods. The method of choice for the
intracellular detection of NMs depends on their characteristics such as
chemical composition, ﬂuorescence, size, and structure as well as on the
cellular structure of interest (for a review see: (Elsaesser et al., 2010;
Vanhecke et al., 2014)).
The information on intracellular localization of NMs can greatly
help to elucidate mechanisms of NM-cell interactions. Confocal laser
scanning microscopy and ﬂow cytometry have been frequently applied
for studying NM uptake, intracellular traﬃcking and semi-quantitative
estimation of the uptake (Meindl et al., 2017). Some NMs, such as metal
NMs, can be detected in cells via ﬂow cytometry without additional
modiﬁcation by using the side scattering intensity signals (Zucker et al.,
2016). However, often NMs require ﬂuorescent labels. This can be a
potential drawback of these techniques as such ﬂuorescent modiﬁca-
tions of NMs can substantially alter their biological behaviour com-
pared to the non-labelled equivalents. In addition, especially with ﬂow
cytometry, the results can be misleading as it is diﬃcult to distinguish
the association of NMs with cells from the actual cellular uptake. Al-
ternatively, “imaging ﬂow cytometry” is an integrative approach
combining ﬂow cytometry analyses with confocal microscopy (Vranic
et al., 2013).
Furthermore, ICP-based techniques coupled with MS (Armand et al.,
2016a; Pang et al., 2016; Huo et al., 2015b) or atomic emission spec-
troscopy (Albanese et al., 2013) cannot distinguish between inter-
nalized NMs, extracellularly associated and/or just located between
cells or within the extracellular ﬂuid (reviewed in: (Collins et al.,
2017)). However, this can be overcome by comparing NM uptake at
37 °C and at 4 °C: at the lower temperature, cells enter an energy-de-
pleted state as well as the membrane rigidity is increased which dis-
ables both the energy dependent NM uptake as well as passive diﬀusion
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through cell membranes (Vranic et al., 2013)]. Hence, at 4 °C no NM
uptake is expected hence the entire signal from NMs is located extra-
cellularly whereas at 37 °C both uptake of NMs and adherence onto
cells occur. NM uptake can be estimated by subtracting measurement at
4 °C from that at 37 °C. On the other hand imaging techniques, such as
hyperspectral dark ﬁeld microscopy, enable intracellular detection of
NMs based on the scattered light from the sample (Shannahan et al.,
2015). Similarly, ion beam microscopy techniques, such as micro-
proton-induced X-ray emission and micro-Rutherford backscattering,
are powerful tools for spatially resolved elemental imaging and quan-
titative analysis at the single cell level (Armand et al., 2016a).
Frequently, TEM (Huk et al., 2014; Gliga et al., 2014; Mu et al.,
2014; Huk et al., 2015a; Goode et al., 2015) or confocal Raman mi-
crospectroscopy (CRM) (Romero et al., 2011; Brautigam et al., 2014)
are employed for a semi-quantitative space-resolved imaging ap-
proaches for simultaneous visualization of NMs and biological en-
vironment at a sub-cellular level (reviewed in: (Collins et al., 2017)).
Namely, TEM with a resolution range from Angstrom to nanometer is
the method of choice for resolving electron dense NMs and, when
coupled to X-ray energy-dispersive spectrometry, it enables chemical
identiﬁcation of NMs present inside or around the cells. However, TEM
is relatively cost-intensive and time-consuming, and is also not applic-
able for non-electron dense NMs; therefore it is not recommended for
the ﬁrst step evaluation of NM hazard assessment. CRM can overcome
restrictions of optical microscopy (low resolution) and electron micro-
scopy (cell destructive approach), it is economical and relatively fast
(involving minimal sample preparation) and thus it can be re-
commended for the intracellular detection of NMs. Even though spatial
resolution is limited compared to electron microscopy, the detection of
unlabelled NMs and agglomerates in cells and tissue with CRM is sen-
sitive and speciﬁc enough for the regulatory purposes (Brautigam et al.,
2014). It is applicable also for time course imaging of individual cells
and tracking cell metabolism of most cell types upon exposure to most
NMs.
3.5. Translocation of NMs across tissue barriers
Numerous reports have shown that NM may overcome existing
barriers such as lung, skin and gut and enter the blood circulation
(Muhlfeld et al., 2008; Lundquist and Artursson, 2016; Lipka et al.,
2010; Kreyling et al., 2014; Jatana and Delouise, 2014).
Most of monoculture or multicellular in vitro systems mimicking an
epithelial barrier are cultivated on Transwell® membrane systems
consisting of permeable membranes separating the apical and baso-
lateral compartment. The pitfall of these systems is that the membranes
are relatively thick, i.e. up to 10 μm, and adherence of NMs to the
membranes can occur. Hence, depending on the composition and pore
size, the membranes per se might, hamper translocation of NMs (Dekali
et al., 2014; Braakhuis et al., 2015). Therefore, more realistic in vitro
translocation models are required to reduce the membrane thickness
and/or the material (Jud et al., 2015).
Several in vitro models are available to test the translocation of NM
which can help to estimate the in vivo internal exposure (Braakhuis
et al., 2015). NM penetration through tissue barriers can be evaluated
with the dermal penetration assay in vitro (OECD TG 428 (OECD,
2004)). With this approach also assessment of skin absorption rates is
feasible, yet this has been shown for chemicals (not NMs) (Fabian et al.,
2017). However, validation of these systems using animal data is still
lacking. Another approach is to use experimental data combined with in
silico models allowing to predict the human bioavailability of NMs in
vivo based on their in vitro translocation rate (Bachler et al., 2015) but
again, in vivo data is required to test the power of such systems. The in
vitro biokinetics research reviewed herein did not yet show a clear re-
lationship between localisation and MOA.
However, reports on very low, or almost no barrier penetration by
NMs has been observed in several in vitro studies. For example, some
titanium dioxide and zinc oxide formulations did not penetrate the
healthy skin barrier (reviewed in: (Monteiro-Riviere et al., 2011;
Landsiedel et al., 2012)), and only minor translocation across the lung
and intestinal barriers (reviewed in: (Braakhuis et al., 2015)). This
again depends on size and material as reported by Kreyling and co-
workers who found a size-dependent translocation of gold NPs across
the air-blood barrier in rats (Kreyling et al., 2014).
3.6. Omics approaches for identiﬁcation of MOA
Omics tools such as transcriptomics, proteomics, genomics/epige-
nomics, and metabolomics have mainly been used in eﬀects-oriented
nanosafety research for the purpose of hazard identiﬁcation, and less
for biomonitoring, or identiﬁcation of speciﬁc biomarkers. Such ap-
proaches can present a supporting tool in elucidating the prevailing
mechanisms of NM toxicity; however improvements in the correlation
of such omics data sets with in vitro studies are required (Riebeling
et al., 2017). Some promising outcomes have been reported, yet it is
important to keep in mind that the approaches can present biases by the
researcher and not so much of the methods themselves (Costa and
Fadeel, 2016). Also, it has often been suggested that some biological
eﬀects of NMs can be manifested only after a normal cellular function
has been challenged (e.g. after pathogen recognition) (Costa and Fadeel,
2016; Kodali et al., 2013).
When coupled with an appropriate bioinformatics evaluation, some
omics approaches have resulted in the indication of novel and/or low-
dose eﬀects that had not been captured by conventional cellular assays
(reviewed in: (Costa and Fadeel, 2016)). For example, a secretomic
approach which is a proteomic analysis of proteins released into the
supernatant has revealed some key events in the NM eﬀect; some major
diﬀerences were observed in the inﬂammation-related proteins and
apoptosis induced in macrophages upon exposure to carbon nanotubes
with respect to asbestos materials (Palomaki et al., 2015). Also, based
on a microarray-based approach combined with secretomics, a so-called
“no observed transcriptomic adverse eﬀect level” was introduced. This
suggests transcriptomics could be applied to benchmark potentially any
type of toxicant, alone or in a mixture, in a predictive risk assessment
framework (Pisani et al., 2015).
Overall, generation of this type of omics data presents the ﬁrst step
in identifying adverse outcome pathways describing toxicological key
events starting from the ﬁrst molecular interaction to the ultimate ad-
verse outcome that can be quantitatively modelled using bioinformatics
approaches. The combination of omics methods will support the
knowledge of MOA that can then give evidence for grouping ap-
proaches for NMs (Riebeling et al., 2017).
Complementary to the majority of the endpoints evaluated in in vitro
studies, use of omics approaches is recommended. They can be used for
comparison of diﬀerent in vitro settings, or compared to in vivo sce-
narios: after exposure to NMs, gene expression proﬁling approaches
have conﬁrmed closer resemblance of co-cultures in vitro to the in vivo
situation, compared to monocultures in vitro. This suggests that co-
cultures of relevant cell types can provide an improved system for high-
throughput in vitro testing, and may reduce the need for animal testing
of NMs (Snyder-Talkington et al., 2015). The bottlenecks so far are that
only limited numbers of NMs have been tested, and costs and protocols
for nanomaterial omics analyses are emerging. Therefore, diﬀerent cell
types and animal experiments should be included and more data is
needed to validate individual co-culture systems before clear conclusion
and recommendations about the applicability of these methods can be
made.
3.7. Cellular reactions
3.7.1. Cytotoxicity
Regardless of the method, both primary cells and cell cultures are
sensitive to alterations in their environments (e.g. temperature and pH
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ﬂuctuations, nutrient and waste concentration) prior to the addition of
a tested substance, e.g. NMs. Therefore, it is important to control cell
culture conditions in order to ensure that the measured cytotoxicity
observed is due to NM eﬀects rather than unfavorable culture condi-
tions (Landsiedel et al., 2010).
Cytotoxicity assays can be classiﬁed based on the experimental
approach for detection of cell death:
(i) via visualization of cellular morphological alterations using e.g.
phase-contrast microscopy or (ii) via colorimetric or ﬂuorimetric ana-
lysis. These methods (ii) can be further categorized into assays that
assess plasma membrane integrity and the ones based on the cellular
metabolism, e.g.mitochondrial activity (Lewinski et al., 2008) and were
used in the majority of the reviewed studies. (iii) Depending on the
research question, ﬂow cytometry is frequently used for determination
of speciﬁc mechanisms of cell death, i.e. for necrosis and apoptosis
evaluation. (iv) As oppose to the cell death evaluation, proliferation can
be used as a measure of cell viability/cytotoxicity of a substance. (v)
Finally, cytotoxic action of NMs can be accessed via epithelial cell
barrier damage.
(i) Cellular morphology visualization.
Solely the use of visualization techniques for determination of NM
cytotoxicity might not be suﬃcient. It is recommended to use those
techniques as a complementary tool to other cytotoxicity assays (de-
scribed under (ii)).
(ii) Colorimetric or ﬂuorimetric analysis.
(a) Compromised membrane integrity assessment.
To start with, exposure to NMs might results in compromised cell
membrane integrity which allows leaking of cellular contents. Such cell
viability assessment includes the neutral red uptake (NRU), trypan blue
(TB) and lactate dehydrogenase (LDH; cytosolic enzyme) release assays
(Stoehr et al., 2011; Gliga et al., 2014; Farcal et al., 2015; Goode et al.,
2015). The principle of the NRU assay is based on the accumulation of
the cationic dye in lysosomes upon crossing plasma membranes by
diﬀusion. Spectrophotometric measurements of the cells exposure to
neutral red allow distinguishing between live and dead cells as the
uptake is decreased or the dye can be leaked out in the case of ruptured
plasma membranes. Diﬀerently, TB dye is only permeable to cells with
compromised membranes: dead cells are stained blue while live cells
remain uncoloured. The amount of dead cells is usually determined via
light microscopy. Similarly, the cytosolic enzyme LDH is released in the
supernatants only from cells with compromised plasma membranes.
Cell death is calculated based on the spectrophotometrically upon ad-
dition of reagents (tetrazolium based salts) enabling colorimetric re-
action with the enzyme.
(b) Assessment of altered cellular metabolism (metabolic activity).
In order to determine the mechanisms behind the induced cell
death, other colorimetric/ﬂuorimetric cytotoxicity assays are being
used in order to determine the mechanism behind the induced cell
death, for example MTT (Armand et al., 2016a; Mu et al., 2014), MTS
(Anguissola et al., 2014; Shannahan et al., 2015; Goode et al., 2015),
WST-1 or resazurin (Farcal et al., 2015) assays. Tetrazolium salts can as
well be used for evaluation of mitochondrial activity as mitochondrial
dehydrogenase enzymes cleave the tetrazolium ring; these enzymes are
functional only in active mitochondria (in viable cells). All those assays
are based on the detection of dehydrogenase activity in viable cells.
Therefore, all the testing conditions (e.g. presence of NMs or chemicals)
can aﬀect dehydrogenase activity or react with the reducing agents to
generate formazan. This can cause discrepancy between the actual vi-
able cell number and the cell number determined.
As high potential for NM interference with diﬀerent cytotox-
icological assays has been proven (Stone et al., 2009), each in vitro test
system has to be evaluated for each individual type of NM to accurately
assess for possible interferences (Kroll et al., 2012). The light absorption
due to the presence of NMs can be corrected for the NM dispersion
alone in the absence of cells (background subtraction) (Mu et al., 2014),
however this is not always accurate as agglomeration and
sedimentation of NMs can be diﬀerent in the presence or absence of
cells (Farcal et al., 2015; Kroll et al., 2012; Guadagnini et al., 2015). In
order to elucidate the potential interference of NMs with any assay, one
can compare the signals from the following: (i) the NMs dispersed in
cell culture media alone, (ii) the cells exposed to the respective NM-
containing medium, and (iii) untreated cells with NMs added later; the
added value of the test under (iii) is to compare if the interference of
NMs alone in cell culture medium diﬀers from that in cell culture
medium with conversed formazan (in the case of tetrazolium salt based
assays, such as MTT and LDH), and (iv) the last measurement is done on
(ultra/high speed) centrifuged supernatants from the NM-exposed cells
so that potentially formed NM agglomerates can be removed. Based on
these outcomes, depending on the severity and type of interference,
some conditions (e.g. the highest NM concentrations) can be excluded
from the following experiments.
(iii) Cell death evaluation: apoptosis and necrosis assays.
The evaluation of apoptosis and necrosis, i.e. programmed vs. acci-
dental cell death, is often used as the ﬁrst stage of NM toxicity eva-
luation. The apoptotic/necrotic cell proportion is usually estimated by
ﬂow cytometry: Annexin-V for loss of membrane asymmetry (apop-
tosis) is coupled with propidium iodide to detect necrotic cells. Since
both the forms of cell death have been reported for cells after exposure
to NMs (Kumar et al., 2015), testing for both is recommended.
(iv) Cell proliferation evaluation.
At the moment, the colony forming eﬃciency (CFE; platting eﬃ-
ciency) assay, is considered one of the most promising tests for general,
ﬁrst step NM toxicity evaluation (Dusinska et al., 2015). The method
has been proven reliable, transferable and has been suggested useful as
an early/ﬁrst stage screening method (Kinsner-Ovaskainen et al.,
2014). CFE is an example of a cell viability method that has been im-
plemented in the genotoxicity testing (e.g. in the OECD TG 476 (OECD,
2015a)) as the ﬁrst step in the genotoxicity assessment of chemicals.
The CFE assay has been recommended as preferred over a test where
interference with NMs cannot be excluded, however its applicability for
multi-cellular systems has not yet been proven.
(v) Estimation of epithelial cell barrier damage: impedance-based
measurements.
Another approach which enables the overcoming of interferences of
NMs with cytotoxicity assays are impedance-based devices. They enable
label-free alternatives to be used for evaluation of adherent cells (when
adhered = viable) and integrity of (epithelial/endothelial) cell barrier.
There are several commercially-available impedance devices that allow
for sensitive real-time observations of cell changes (cell viability, mo-
tility, adhesion) upon exposure to NM throughout an experiment
without the need for destructive cell sampling. It is applicable for a
range of NMs and cell types. Reliability and eﬃciency of impedance-
based methods have been compared with conventional cytotoxicity
assays used for assessment of NM induced cellular damage (reviewed
in: (Collins et al., 2017). Such approaches have been recently re-
commended for initial, ﬁrst step, evaluation of material toxicity parti-
cularly for barrier systems (Collins et al., 2017).
3.7.2. Oxidative stress evaluation
Oxidative stress is the prevailing paradigm in the NM induced ef-
fects in vitro as it is linked to various adverse outcomes such as (pro-)
inﬂammation, DNA damage, and general cytotoxicity. Cells generate
ROS to maintain normal metabolism/homeostasis, but its over-
production can interfere with a variety of signal transduction pathways,
even induce cell apoptosis. ROS detection in cells often uses ﬂuorescent
or non-ﬂuorescent probes such as dihydroethidium or dichloro-
ﬂuorescein (DCF) (Gliga et al., 2014; Goode et al., 2015; Driessen et al.,
2015). On one hand, this approach allows for investigation of early
intracellular ROS indicators at much lower NP concentrations than
those needed for standard cytotoxicity assays, but on the other hand
interference with NMs has been observed e.g. for multi-walled carbon
nanotubes (Roesslein et al., 2013), graphene-based materials
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(Creighton et al., 2013), cadmium selenide, titanium dioxide (Ong
et al., 2014), iron oxide (Doak et al., 2009) and gold (Pfaller et al.,
2010) NPs and thus can limit the range of tested particle concentra-
tions. Therefore, an alternative method to report on cellular ROS gen-
eration induced by NMs is highly needed, such as a proteomic-based
analysis of protein carbonylation as an oxidative stress measure
(Driessen et al., 2015). As a complementary approach to this or prior
the cellular experiments, acellular measurement methods are re-
commended for the evaluation of the potential of NMs to generate ROS
already in the suspension medium such as the ESR approach for indirect
assessment of surface reactivity (Driessen et al., 2015; He et al., 2014).
As addressed in the Section 2 (General considerations for in vitro test
methods), ROS can be detected also via e.g. cytochrome c reduction
(Dikalov and Harrison, 2014; Delaval et al., 2017) or FRAS assay
(Braakhuis et al., 2014). In addition, measurements of the photo-
sensitized oxidation of dyes or ROS quenchers such a furfuryl alcohol or
tert-butanol from solution in batch experiments can also be used to
measure the ROS production rates for NMs' suspensions (Pickering and
Wiesner, 2005).
3.7.3. (Pro-)inﬂammatory reactions
The analysis of the secreted soluble factors i.e. proteins such as
cytokines, chemokines and growth factors are usually determined by
the enzyme-linked immunosorbent assay (ELISA) (Huk et al., 2014;
Wan et al., 2015; Farcal et al., 2015; Goode et al., 2015). It is based on
the enzymatic reaction analysed with ﬂow cytometry, or using a plate
reader (absorbance, chemoluminescence or ﬂuorescence measure-
ments). However, with all these approaches, interference with NMs in
cell culture supernatants or tissue/cell lysates is possible. The outcomes
must be interpreted with respect to the cell viability data as the loss of
cell viability at higher doses of NMs could prevent the cytokine secre-
tion and thus lead to false negative results. In addition, due to the high
protein adsorption capacity of some of the NM types, the released
proteins (e.g. cytokines) have the possibility to adhere to the NMs and
thus the protein/cytokine concentration may be underestimated as
demonstrated for titanium dioxide, silicon dioxide and iron oxide NPs
(Guadagnini et al., 2015). Therefore, instead of, or in parallel with, the
cytokine release assessed with ELISA, the gene expression can be
evaluated using the reverse transcription polymerase chain reaction
such as for the selected pro-inﬂammatory genes' expression (Shannahan
et al., 2015), or i.e. reporter cell lines can be used for that purpose
which has been e.g. proven for transfected A549 cell line (Stoehr et al.,
2011).
Overall, the cytotoxicity assays should always consider the cell type
and MNs used, so therefore a generalized recommendation cannot be
given. A battery of tests should be employed, along with an appropriate
medium, time of exposure, appropriate controls and reference stan-
dards used, multiple in vitro cytotoxicity assays (including dye-free
approaches), at least three representative cell lines (including diﬀerent
cell lines originating from the same organic system) (Kroll et al., 2011),
ﬁve concentrations of MNs, and must include corresponding negative
and positive assay controls; both the assay-speciﬁc ones and the NM-
based controls are advised (discussed in the section 3.7.7: Positive and
negative controls). For suspension experiments in which a dye is re-
quired, interference tests are mandatory. Conventional toxicological
(and genotoxicological) assays have been developed to test soluble
chemicals and not NMs. For that reason, individual cytotoxicity
methods alone are currently not suﬃcient for evaluation of toxic po-
tential of NMs. Prior evaluation and adaptation of the assays is re-
commended; further, multiple assays need to be employed for a reliable
nanotoxicological assessment (Landsiedel et al., 2010; Kroll et al.,
2011). These assays are commonly based on detection of light or
ﬂuorescence of a marker or chemical reaction products, therefore
possible interference of NMs with the assay reagents or optical pathway
needs to be carefully considered (Landsiedel et al., 2010). NM-speciﬁc
adaptations of the conventional cytotoxicity assays (e.g. MTT and DCF
assays) might eliminate NM interference with the method, thus still
limited with high NM concentration (Kroll et al., 2012). In addition, in
vitro assays are often pH-dependent hence the outcomes may be af-
fected by acidic or basic NMs. Therefore, particularly in the case of NM
concentrations exceeded the buﬀer capacities of biological media,
acidity/alkalinity testing is recommended (Landsiedel et al., 2010).
3.7.4. Genotoxicity
Genotoxicity describes the potential damage of NMs to the genetic
material in a cellular nucleus, i.e. DNA. In general, NM-induced geno-
toxicity can be classiﬁed as primary or secondary genotoxicity. Primary
genotoxicity is deﬁned as genetic damage induced by NMs themselves
and not by an inﬂammatory response, whereas secondary genotoxicity
implies involvement of inﬂammatory cells resulting in the oxidative
damage of DNA by ROS (Van Berlo et al., 2012; KEMI, 2016; Nabiev
et al., 2007). Conceptually, primary genotoxicity can be induced via
direct or indirect mechanisms. The direct genotoxicity results from
physical interactions of the materials with the genomic DNA which can
occur for smaller NMs capable of reaching the nucleus through the
nuclear pore complexes (Nabiev et al., 2007). Indirectly caused genetic
damage can occur via various pathways; for instance via formation of
ROS by metals and organic constituents (but not inducing inﬂamma-
tion) (Schins and Knaapen, 2007).
The OECD workshop ﬁndings (OECD, 2014d) provide very useful
recommendations on genotoxicity testing in vitro. We agree on the in-
appropriateness of the bacterial based tests (such as Ames test (OECD
TG 471 (OECD, 1997)) for genotoxicity of NMs due to the reasons
stated in the OECD document (OECD, 2014d). Namely, uptake of NMs
in bacterial cells can be limited due to the lack of endocytotic ability of
bacteria used in the assays and diﬀusion of NMs across the bacterial cell
wall may be limited the pores of the Ames Salmonella assay bacterium
are< 30 nm. As reviewed by Landsiedel and colleagues in 2009, the
outcomes of the Ames assay for all the NMs tested (e.g. zinc oxide, ti-
tanium dioxide, magnetic NPs) were negative (Landsiedel et al., 2009).
In addition, some NMs have antibacterial properties which can lead to
misinterpretations of the outcomes. In some cases, the size of bacteria
can be even smaller than some types of NMs (Huk et al., 2014; Doak
et al., 2012). As an alternative, in vitro mammalian cell gene mutation
assay OECD TG 476 (OECD, 2015a) has been suggested (OECD, 2014d).
For that assay, the use of an appropriate cell type is recommended e.g.
the ones with a shorter cell cycle (12 h). However, to date, there are
only few studies using this test (Huk et al., 2014; Huk et al., 2015a) and
there has been no evidence in interference of NMs; therefore the ap-
proach is recommended, but further testing is required.
Another recommendation from the workshop was to consider spe-
ciﬁc modiﬁcations of the in vitro mammalian cell micronucleus assay
(OECD TG 487 (OECD, 2014b)) which is used for evaluation of chro-
mosome breakage leading to the formation of an additional nucleus
(micronucleus) during cellular division. To prevent cytokinesis in the
test, treatment with Cytochalasin-B (CyteB) is usually used; however
this has been proven to strongly aﬀect NM uptake (KEMI, 2016),
therefore, post-treatment or delayed co-treatment with Cyt-B has been
suggested (Gonzalez et al., 2011; ANSES, 2013). As of now, it can be
reported that the OECD started to develop a guidance document on the
NM-speciﬁc adaption of the in vitro mammalian cell micronucleus assay
(OECD, 2015e).
Additionally, comet assay has been reported as a successfully ap-
plied approach for genotoxicity evaluation for NMs (Huk et al., 2014;
Dusinska et al., 2015; Magdolenova et al., 2014); however the method
is limited due to possibly interference with induced cytotoxicity upon
incubation with the tested NMs – this can signiﬁcantly impair reliable
genotoxicity evaluation (Huk et al., 2015b). Also, false positive results
have been reported due to presence of NMs in the ‘comet head’ which
has raised concerns of the possible interference of the previously up-
taken NMs with the assay components (Ferraro et al., 2016). Hence, the
comet assay is an appropriate method for NMs' genotoxicity testing, but
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only in combination with cytotoxicity evaluations so that genotoxicity
can be related to concentrations above 80% viability. Other genotoxi-
city assays include e.g. the γ-H2AX foci formation as a marker for DNA
double strand breaks which might provide higher sensitivity of the
comet assay but with limited mechanistic insight for investigations of
more precise mechanisms of genotoxicity (Gliga et al., 2014). Also the
in vitro mammalian chromosome aberration OECD TG 473 (OECD,
2014c) and in vivo mammalian bone marrow chromosomal aberration
OECD TG 475 (OECD, 2014e) tests might be suitable solutions also for
NMs, yet only upon further testing for NMs.
Similar to the cytotoxicological methods, use of chemical and NM
positive and negative controls is required for veriﬁcation of individual
genotoxicity assays in vitro: negative controls should elicit the back-
ground level of DNA damage, whereas positive controls should show
highly signiﬁcant damage, corresponding to the type of the damage
which is measured with the individual assays used (Huk et al., 2015b).
(In more details discussed in the section 3.7.7. Positive and negative con-
trols).
Nevertheless, a recommended approach is to compare the outcomes
of in vitro genotoxicological assays with that of the equivalent in vivo
assay using the same NM dispersion and comparable exposure duration.
However, some discrepancies can occur between both the settings. For
instance, absence of genotoxic eﬀects of gold NPs have been observed in
comet/micronucleus in vivo and in vitro settings, whereas DNA damage
induced by crystalline silica (quartz, DQ 12) NMs was measured in the
in vivo Comet and micronucleus assays, but not in vitro (Downs et al.,
2012). Oppositely, comparable concentrations of NMs can induce eﬀect
in vitro with absence of observed damage in vivo (even with pronounced
inﬂammation reaction) which can be explained with the fact that
considerably lower doses may reach the target cells in vivo than in vitro.
From a regulatory perspective, genotoxicity testing requires a bat-
tery of tests addressing diﬀerent genotoxic and mutagenic endpoints,
since no single method is capable of detecting all the diﬀerent forms of
genome damage which includes DNA lesions, chromosome aberration
and mutations (Huk et al., 2015a; Doak et al., 2012). The current re-
commendations on genotoxicity of NMs are: (i) the use of mammalian
tests over bacterial cells (as the later have limited ability to engulf
MNs), such as the modiﬁed in vitro mammalian cell micronucleus assay
OECD TG 487 (OECD, 2014b) or the in vitro mammalian cell gene
mutation assay OECD TG 476 (OECD, 2015a) (ii) the use of non-cyto-
toxic concentrations; appropriate cytotoxicity tests should be part of the
genotoxicity testing strategy, (iii) prolonged time (at least 24 h) of the
treatment is recommended to ensure MN uptake by cells and access to
DNA when the nuclear membrane is dissolved. Outcomes of the geno-
toxicological assays vary signiﬁcantly at intra- and inter-laboratory
comparisons. The reasons are mostly attributed to diversity of NM
preparation and handling, therefore parallel studies with other end-
points are important (Huk et al., 2015b; OECD, 2015e; Pfuhler et al.,
2013).
3.7.4.1. Carcinogenicity in vitro: Colony Transformation Assay
(CTA). Besides the abovementioned approaches for evaluation of
genotoxicity of NMs in vitro, there has been promising new
approaches proposed. As an example of a complementary approach to
in vitro genotoxicity test batteries is the i.e. Cell Transformation Assays
(CTA) which measure potential cell transformation (that is one step in
the multistep cancer process), and can detect both genotoxic and non-
genotoxic carcinogens (Steinberg, 2017). In 2015, European Union
Reference Laboratory for alternatives to animal testing (EURL-ECVAM)
issued a Guidance document (protocol) proposing to use the “In vitro
syrian hamster embryo (SHE) cell transformation assay” as part of a
weight of evidence approach in the testing of substances for
carcinogenic potential. Until now, only few results are available for
NMs (Ponti et al., 2009; JRC, 2016) and further testing is required
before issuing a ﬁnal recommendation.
3.7.5. Other relevant endpoints
3.7.5.1. Immunotoxicity testing. Regardless of the route of exposure, NM
will eventually come in contact with immune cells and reports have
shown this may trigger adverse immune eﬀect (Farrera and Fadeel,
2015) (and reviewed in: (Giannakou et al., 2016b; Fytianos et al.,
2016). Eﬀects of NM on the immune system have been described and
recommendations from the 2008 National Cancer Institute workshop on
immunology and nanotechnology have been proposed in terms of the
immune cell models, mono- as well as co-culture systems, being suitable
for a ﬁrst evaluation of NM immunomodulatory eﬀects (Dobrovolskaia
et al., 2009). However, at the moment, there are no speciﬁc regulatory
documents available for general immunotoxicity assessment of NMs
(apart from some speciﬁc NM formulations). The adverse eﬀects are not
always readily detected using the conventional immunotoxicity
methods; a battery of such NM-speciﬁc assays is required to assess
NM eﬀect on the immune system (Giannakou et al., 2016b).
3.7.5.2. High aspect ratio nanomaterials (HARN). In addition, HARN,
such as carbon nanotubes, have been shown to induce (pro-)ﬁbrotic
responses both in vivo and in vitro, whereas the severity of the response
is dependent on their physico-chemical characteristics (Vietti et al.,
2016). Therefore this endpoint is recommended to be tested for ﬁbre
shaped NMs.
3.7.6. Multiple endpoint approaches
The combination of multiple endpoint-approaches such as the high
throughput screening and the high content analysis has been proposed
as promising approaches for fast cytotoxicity screening of a large panel
of NMs (Anguissola et al., 2014) within hazard and risk assessment
frameworks. However, similar possible NM interferences with assays
reagents and optical pathways need to be considered as well as the
appropriate positive and negative controls (discussed below).
3.7.7. Positive and negative controls
It is very important to mention that for all the assays described
above at least chemical positive and negative controls have to be sys-
tematically included in experiments for quality control, to demonstrate
correct performance of the assays and to ensure reproducibility (Huk
et al., 2015b). Besides chemical controls, also NM-based controls are
recommended in order to conﬁrm the sensitivity of the techniques for
NMs, to benchmark the NM biological eﬀects, and in some cases also to
assess potential NM interferences with the assay (Dusinska et al., 2015;
Collins et al., 2017). Usually, untreated cells are used for negative
controls and the assay data are presented normalised to these values
(e.g (Huk et al., 2014).), whereas in some cases, the respective bulk
materials are used (Wiemann et al., 2016). The majority of the studies
under review compare the NM-induced eﬀects with those caused by
chemicals, e.g. H2O2 for cell viability, oxidative stress and genotoxicity
(Armand et al., 2016a), LPS (Chortarea et al., 2015) or TNF-α (Huk
et al., 2014) for the onset of inﬂammation, or respective salts (Stoehr
et al., 2011; Mu et al., 2014). In most of the respiratory exposure-re-
lated studies, the same positive controls (chemicals (Clift et al., 2014)
or DQ 12 (Chortarea et al., 2015; Wiemann et al., 2016)) are applied for
all the endpoints. Only in some studies has NM-based reference material
been reported, e.g. amine modiﬁed polystyrene NPs (Anguissola et al.,
2014; Paget et al., 2014) as positive controls for cytotoxicity, oxidative
stress, genotoxicity or apoptosis and activation of the inﬂammasome
pathway and reviewed in: (Collins et al., 2017). In some studies, ma-
terial with the same chemical composition but diﬀerent morphology is
used for positive control (e.g. long silver nanowires for cytotoxicity and
cell death (Stoehr et al., 2011)) whereas poly-lactic-co-glycolic acid–-
polyethylene oxide copolymer coated NPs or carboxylated nanodia-
monds are examples of particle negative controls for cyto-and geno-
toxicity (Dusinska et al., 2015; Paget et al., 2014).
However, there is a considerable challenge in nanotoxicology to
advise suitable nano-speciﬁc positive as well as negative controls
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(Dusinska et al., 2015; Huk et al., 2015b). Up to date, there has not yet
been a generally accepted recommendation given for nano-speciﬁc re-
ference controls and standards since this does not only depend on the
endpoint but also on the exposure route. As one example for cytotoxi-
city and apoptosis it is recommended to use the amine modiﬁed poly-
styrene NPs as a positive control NM, and their neutral equivalents
(plain polystyrene NPs) or carboxylated polystyrene NPs for negative
controls (Anguissola et al., 2014); for inﬂammation DQ 12 has been
shown to be the most promising positive control, especially in respect to
the inhalation route of exposure (Oberdörster et al., 2005). However,
for genotoxicity, we agree with the proposal by Pfuhler and colleagues
that NM-speciﬁc positive controls were not considered to be necessary
for genotoxicity assays, because positive controls in this case relate to
assay performance (Pfuhler et al., 2013).
Overall, a combination of system control measurements and inter-
laboratory comparison data is recommended to be performed for each
individual cytotoxicity method to get an insight about the relative
sources of assay variability, which can be more distinctive for NMs
(compared to chemicals). The interlaboratory comparison of the MTS
assay in vitro using A549 cells, recently provided by Elliot and the
colleagues (Elliott et al., 2017), proposes that even using the same NM
and cell type as well as the same assay, researcher's experimental per-
formance may strongly inﬂuence the cytotoxicity assay outcomes. For
example, the cell line source, media exchange, cell handling, and NM
dispersion preparation and application to cells are critical to ensure
protocol robustness and comparability of results. These general con-
cepts should be applicable to most nanotoxicological tests.
4. Regulatory relevance: testing strategy
4.1. Categorization
The “grouping” concept of NMs aims to increase the hazard as-
sessment of any material in a more eﬃcient manner and with the
possibility of cross-reading of toxicological properties. Such eﬀects of
an unknown substance might be predicted from endpoint-speciﬁc ef-
fects of the other substances classiﬁed in the same group. However, so
far, no regulatory framework for such grouping approaches of NMs
exists, but various eﬀorts on this are described in the literature (Dekkers
et al., 2016; Arts et al., 2016; Arts et al., 2015; Bos et al., 2015;
Oosterwijk et al., 2016; Walser and Studer, 2015; Hendren et al., 2015).
A systematic approach which is called “The Read-Across Assessment
Framework” has been proposed by the European Chemicals Agency
(ECHA) (ECHA, 2017). This framework uses relevant information from
analogous substances to predict the properties for other, similar sub-
stances. However, this has been proposed for chemicals and it is
questionable if such an approach also can be applied to NMs.
For example, the National Institute for Occupational Safety and
Health (NIOSH) and the British Standardization Institute (BSI) distin-
guish between: (i) soluble, (ii) biopersistent and low toxicity, (iii) bio-
persistent and high toxicity, and (iv) ﬁbrous NMs, i.e. HARN (Kuempel
et al., 2012). Other grouping eﬀorts reported by German Federal In-
stitutes BAuA and BAM or the EU Commission have been reviewed by
Arts et al. (Arts et al., 2014).
The European Centre for Ecotoxicology and Toxicology of
Chemicals Task Force on Nanomaterials (ECETOC Nano TF) (Arts et al.,
2016; Arts et al., 2015) has proposed a functionality-driven Decision-
making framework for the grouping and testing of NMs (DF4nano-
Grouping) with the aim to group them by their speciﬁc MOA that re-
sults in an apical toxic eﬀect. The following three tiers to assign NMs
into four main groups have been proposed, based on the data including
24 tested materials in speciﬁc case studies:
• DF4nanoGrouping Tier 1 – intrinsic material properties: water so-
lubility, particle size and shape (aspect ratio) and composition, in-
cluding surface functionalization, and noting the presence of
material components or impurities;
• DF4nanoGrouping Tier 2 – system-dependent properties and in vitro
eﬀects: dissolution in biological media, surface reactivity, dis-
persibility, cellular eﬀects and in vitro genotoxicity;
• DF4nanoGrouping Tier 3 – in vivo eﬀects: apical toxic eﬀects, toxic
potency, in vivo genotoxicity, reversibility of eﬀects, (primary and
secondary) organ burden and clearance, biodistribution and bio-
persistence;
• DF4nanoGrouping – qualiﬁers: release (dustiness) and supplemen-
tary criteria, such as surface area, surface chemistry, surface charge,
and hydrophobicity.
In addition, surface reactivity of NMs in a cell free setting can
provide a useful tool for prediction of material cytotoxicity. For ex-
ample, it has been shown that the redox potential of NMs measured by
ESR correlated well with the outcomes of the proteomic-based analysis
of protein carbonylation as an oxidative stress measure. Hence, such a
redox proﬁling approach may be used for NM classiﬁcation (grouping)
according to their MOA using e.g. the ESR approach (Driessen et al.,
2015) or the FRAS assay (Riebeling et al., 2016; Hsieh et al., 2013).
Another example of an in vitro assay suitable for regulatory purposes
predicting short-term inhalation toxicity has recently be proposed by
the group of Landsiedel and co-workers (Wiemann et al., 2016) who
tested an in vitro assay using rat derived alveolar macrophages.
A useful approach for ranking NMs has recently (2016) been pro-
posed by the NANoREG project (JRC, 2016) which is in context with the
European Chemicals Agency (ECHA) in the report called “Usage of
(eco)toxicological data for bridging data gaps between and grouping
nanoforms of the same substance – Elements to consider” (ECHA, 2016)
aiming at clarifying rules for read-across and grouping of NMs. To start
with, it is expected that NMs are classiﬁed to have genotoxic and/or
sensitizing properties according to the classiﬁcation of their chemical
core, and the remaining evaluation process to be followed is presented
in Fig. 2 below.
The authors conclude that speciﬁc case studies covering a broad
spectrum of diﬀerent types of NMs should be conducted to provide
further proof-of-evidence for the suggested grouping concept with the
perspective to integrate this into the REACH registration process for
substances that have to be registered in the nanoform.
It is accepted that a single dose parameter is not suﬃcient to de-
scribe the toxic eﬀects of NMs. Therefore other parameters such as size,
surface area, surface reactivity, concentration and exposure time need
to be included as well as diﬀerent endpoints.
In the ﬁrst phase of evaluation, NMs are classiﬁed in 3 categories:
red (the highest potential to be hazardous), green (NMs for which the
classical i.e. the non-NM, risk assessment approach can be performed),
and orange (further evaluation needed). The in vitro part of the process
includes genotoxicity and immunotoxicity evaluation in the phase I and
is continued in the phase II ranking based on occupational and con-
sumer exposure scenarios In phase III, guided by information obtained
on the kinetics and hazard in phase II, additional information on other
endpoints may be obtained by in vivo studies. In the case of observed
positive eﬀects of in vitro cell experiments, transformation of the NMs
itself, and in vitro genotoxicity along with expected accumulation and
immunotoxicity, this may trigger long-term repeated dose kinetic and
toxicity testing in vivo to rule out accumulation and long-term eﬀects,
including carcinogenic, cardiovascular and adverse reproductive eﬀects
(presented as the ﬁnal arrow in the Fig. 2).
5. Final conclusions and recommendations
The authors fully agree with Gordon and the colleagues (Gordon
et al., 2014) who concluded that most in vitro test results we have
available so far for NMs are not suﬃcient in and of themselves for ﬁnal
regulatory decisions on the possible toxicity of a given NM. However,
based on the current literature research we conclude that the existing in
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vitro assays are suitable for identifying the capacity of NM to induce
potential human hazard eﬀects. Hence, in vitro results may be useful in
ranking NMs either as mechanistic studies enabling a deeper insight
into mechanisms of NM-induced (potentially even nano-speciﬁc) ef-
fects, or for follow-on in vivo testing in certain circumstances (Wiemann
et al., 2016), and can also contribute to the interpretation of in vivo
results by identifying their MOA. In addition, the in vitro outcomes can
serve as guidelines for design of in vivo experiments. It is recommended
that several time points are included in the assessment of NMs' inter-
nalization and subsequent cellular response. This might importantly be
aﬀected by the naturally present biomolecules which can adhere on NM
surface. The intracellular distribution pattern of MNs is an important
factor in investigating nanotoxicological responses; however analytical
method of choice depends on the type of the investigated NMs base on
their physico-chemical characteristics.
The behaviour of MNs in physiological ﬂuids is relevant, as is the
Fig. 2. Stepwise approach to categorize NMs according to Deliverable 1.1 of the NANoREG project (Adopted with permission from: NANoREG DR, D. 1.11, 2016 (JRC, 2016)). Green
arrows: the material is no nanomaterial or has such a high dissolution rate in water that it falls apart into its molecular or ionic form before it reaches its target - the classical (non-
nanomaterial) risk assessment approach can be performed. Red arrow: the material is a “rigid and biopersistent High Aspect Ratio Nanomaterial (HARN)” - substitution or information
gathering for targeted risk assessment to evaluated the potential to cause mesothelioma is needed. Orange arrows: the material does not meet the criteria for classical (non-nanomaterial)
risk assessment or targeted risk assessment to evaluate the potential to cause mesothelioma - use information of phase I for prioritisation and/or further evaluation following the proposed
elements related to the kinetics, toxicity and exposure in phase II, III and further. Black arrows: evaluation of the nanomaterial following the proposed elements related to the kinetics,
toxicity and exposure in phase I, II, III and further. PROC = process and operational conditions. I: inhalation route of exposure. O: oral route of exposure. D: dermal route of exposure.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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evaluation of NMs' biodegradability and biopersistence in mimicked
intracellular lysosomal compartments. Many of the more general con-
siderations useful in assessing the reliability of an in vitro test are
summarized in Table 1:
(i) From the publications reviewed we cannot recommend one cell
model which can cover everything, since clearly the models or end-
points might diﬀer for diﬀerent (disease) stages. As a ﬁrst stage hazard
assessment, cell lines are be preferred over primary cells. For initial
screening methods, relevant mono-cultures (i.e. oral, lung, and intes-
tine) and CFE might be suﬃcient but then more complex models and
more endpoints should be included, particularly the long-term eﬀects
mimicking sub-chronic exposures.
(ii) Dose metrics: it is not suﬃcient to provide information about
NM concentration (i.e. μg/mL) or the surface exposed to cells. It is re-
commended that all the three mass metrics are reported (mass, surface
area and number). The deposited dose and/or cell burden has to be
given. Estimation methods are available to provide deposited doses for
submerged cultures, and more realistic dosing methods are available to
more directly measure deposited doses (such as ALI exposure systems).
More studies should be performed using the concentrations expected
with human exposure, namely those concentrations which are occu-
pationally relevant or daily relevant. Companies should make in vivo
data available that would support eﬀorts to optimize and validate cell
culture approaches.
(iii) Cellular uptake of NMs is an important aspect to consider in NM
hazard assessment in vitro. However, attention should be given to
comparison with in vivo situation. A characteristic of in vitro settings is
that most of the cell types (or nearly all) internalize NM that are and
deposited on the cell surface are engulfed. Therefore, the most im-
portant question in vitro as well as in vivo is how many NMs reach the
surface of any speciﬁc cell type. These aspects are covered in the
dosimetry paper within this special issue (Oberdörster et al., 2017 - in
this issue) and are not further explored herein. (iv) Finally, the fol-
lowing tiered testing strategy for cell culture assays is recommended
before in vivo tests are performed:
1. In addition to the physico-chemical characterization of NMs before,
during and after the test performance, protein corona kinetics
during and after the test, analysis of NMs stability/biodurability in
relevant physiological ﬂuids is required.
2. The choice of relevant cell models including thorough character-
ization of cell growth and diﬀerentiation, inclusion of endpoints
mimicking the in situ cell response. Comparison between acute and
long-term eﬀects.
3. Assessment of cellular uptake, biokinetics, inclusion of i.e. screening
methods (omics) to determine MOA.
To summarize, the most important criteria to produce reliable and
robust data from in vitro nanotoxicological assays is: (i) detailed NM
characterization, including physicochemical properties before, during
and after the testing, (ii) use of comparable and realistic dose metrics
and test conditions, (iii) implementation of chemical positive and ne-
gative controls and reference NMs allowing for comparison between
studies, both intra- and interlaboratory. The use of NM-based controls is
recommended. In order to avoid false negative or false positive results,
at least two independent methods per individual tested endpoint need
to be performed and with multiple relevant cell types or co-culture
models and standardized cytotoxicological assays (also reviewed in:
(Farcal et al., 2015)). The choice of relevant cell models includes a
thorough characterization of cell growth and diﬀerentiation along with
the endpoints mimicking the in situ cell response. With respect to the
comparison between acute and long-term eﬀects: for ﬁrst initial
Table 1
Considerations for in vitro testing of NMs, which should lead to increased reliability and relevance.
Topics Recommendations
NM characterization 1. More than one appropriate technique for physico-chemical (PC) characterization (before, during and after the cell experiments).
2. Use of the identiﬁed methods for measurement of the following PC endpoints: primary particle size distribution; hydrodynamic diameter;
volume speciﬁc surface area; agglomeration behaviour; surface reactivity; dissolution kinetics, as applicable; aging of NMs (particularly in
suspension).
3. The importance of individual properties diﬀers with respect to the exposure scenarios.
o Of particular importance: the identiﬁed PC properties of NMs aﬀecting material deposition and clearance from the lungs.
Cell culture characterization 1. Report the cell source, passage number, and precise cell culture method.
o Detailed description of the source and providers (cell culture medium, laboratory cell culturing material), a thorough description of the cell
growth, morphology and diﬀerentiation before and during the test performance.
Cell culture choice 1. A justiﬁcation of the selected cell culture.
2. Cell lines (homogenous and more stable and hence more reproducible; easily accessible) are preferred over the primary cells.
3. Human cell lines are supported (more closely mimic human responses); however, rodent cell line results are more comparable to in vivo animal
data.
4. e.g. Fibroblasts for pro-ﬁbrotic signals, macrophages as primary responders, intestine or lung epithelial cells due to their barrier functions.
Dose metrics/Dosimetry 1. Careful consideration of the dispersion protocol eﬀects for NMs: e.g. avoidance of ROS generation and other eﬀects on NM; avoidance of
stabilizers with toxic or mutagenic potential. Tested for presence of endotoxins.
2. The eﬀects of the protein corona formation should be considered, if possible.
3. Higher importance of the chronic (e.g. repeated) exposures for regulatory risk assessment.
4. High doses are required in mechanistic studies, however it needs to be considered if the concentration of MNs in tests would exceed the level at
which agglomeration is enhanced.
5. Units: mass or number concentration per cell; however it is recommended that all the three mass metrics are reported (mass, surface area and
number). In the likelihood of intracellular NM alterations or dissolution, detection of intracellular NM concentration is recommended.
6. Submerged test conditions: 1–100 μg MNs/mL, with the lower and higher limits at 0.125 and 200 μg/mL. It is recommended that the
concentrations used in the submerged settings do not exceed greatly the level at which agglomeration is enhanced. Deposited dose on the cell
surface needs to be calculated (speciﬁed methods or models).
7. Doses selected should be anchored by known human exposures; conversions from human exposures< -> in vitro exposures are suggested (via
e.g. reverse dosimetry models).
8. Air-liquid interface (ALI) protocols for lung cell experiments may overcome the issue with suspension cultures by a direct deposition of a NM
onto the lung cell surface. Use of ALI (and barrier protocols) avoids the need for many dosimetric conversions since most of the aerosolisation
systems can measure the deposited NM concentration on-line thus allowing to obtain a dose-related eﬀect (Braakhuis et al., 2016)
Cellular responses 1. Multiple assays for individual endpoints should be employed.
2. NM response need to be assessed in multiple (at least three) diﬀerent cell types and/or co-cultures.
3. Possible NM interferences with assay reagents, products or optical pathways need to be considered.
4. Chemical positive and negative controls need to be included in each assay and the use of NM-based negative and positive controls is
recommended.
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screening, mono-cultures seem to be appropriate. However, for more in-
depth mechanistic studies 3D cultures should be preferred. If the hazard
of inhaled NMs is investigated, then the use of ALI lung cell cultures in
combination with dose-controlled NM aerosolisation systems is re-
commended.
Overall, it is foreseen that in vitro methods for NM hazard assess-
ment have the potential to contribute to reduction of animal studies by
setting priorities for further in vivo testing (Braakhuis et al., 2015).
However, as currently the correlation between the in vitro and in vivo
assays is not clariﬁed yet, at the moment in vitro tests per se are not
suitable for NM hazard and further risk assessment. The future direction
should be driven towards standardization and validation of speciﬁc in
vitro assays mimicking deﬁned in vivo endpoints.
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